311.41
-0.71 (-0.23%)
| Penutupan Terdahulu | 312.12 |
| Buka | 317.20 |
| Jumlah Dagangan | 189,286 |
| Purata Dagangan (3B) | 236,033 |
| Modal Pasaran | 32,309,166,080 |
| Harga / Pendapatan (P/E TTM) | 70.30 |
| Harga / Pendapatan (P/E Ke hadapan) | 50.76 |
| Harga / Jualan (P/S) | 6.23 |
| Harga / Buku (P/B) | 6.80 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2026 |
| Margin Keuntungan | -9.40% |
| Margin Operasi (TTM) | 0.99% |
| EPS Cair (TTM) | -3.69 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 48.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 28.49% |
| Nisbah Semasa (MRQ) | 1.96 |
| Aliran Tunai Operasi (OCF TTM) | 212.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -120.68 M |
| Pulangan Atas Aset (ROA TTM) | -3.22% |
| Pulangan Atas Ekuiti (ROE TTM) | -11.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | BeOne Medicines Ltd. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.25 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 17.31% |
| % Dimiliki oleh Institusi | 43.94% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Capital International, Inc./Ca/ | 31 Dec 2025 | 307,660 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 425.00 (RBC Capital, 36.48%) | Beli |
| Median | 411.00 (31.98%) | |
| Rendah | 405.00 (Barclays, 30.05%) | Beli |
| Purata | 413.00 (32.62%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 316.99 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 27 Feb 2026 | 405.00 (30.05%) | Beli | 316.99 |
| Guggenheim | 27 Feb 2026 | 410.00 (31.66%) | Beli | 316.99 |
| RBC Capital | 27 Feb 2026 | 425.00 (36.48%) | Beli | 316.99 |
| Truist Securities | 27 Feb 2026 | 412.00 (32.30%) | Beli | 316.99 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |